Novo's injectable bests oral challenger in growth hormone trial

This Week

Nov 16, 2022

Indivior inks $145M Opiant buyout to add nasal opioid overdose drug to portfolio

TriSalus inks SPAC merger to fund cancer trials of pressure-enabled drug delivery technology

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis

PharmaJet inks deal to use needle-free delivery tech in polio vaccination campaign

The Top Line Podcast: don’t miss out on the newest episode where we discuss ASCO data, rising health tech stars, and more. Listen now.

 

Featured

Indivior inks $145M Opiant buyout to add nasal opioid overdose drug to portfolio

By Nick Paul Taylor

Indivior has snapped up Opiant Pharmaceuticals for an initial $145 million, capitalizing on the fall of the company’s share price throughout the year to add a near-approval nasal formulation of nalmefene to its portfolio.
 

Top Stories

TriSalus inks SPAC merger to fund cancer trials of pressure-enabled drug delivery technology

By Nick Paul Taylor

TriSalus Life Sciences has identified a path to data on its drug delivery device and lead candidate, inking a deal to merge with a special purpose acquisition company and build an anticipated $60 million cash reserve.

Lumos' oral growth hormone drug falls short of Novo's injectable incumbent at interim analysis

By Nick Paul Taylor

Lumos Pharma’s oral treatment for moderate pediatric growth hormone deficiency has failed to match up to Novo Nordisk’s injected drug Norditropin at the interim analysis of a phase 2 trial. But with growth in the Norditropin arm exceeding expectations, Lumos has pinned the blame on baseline imbalances.

PharmaJet inks deal to use needle-free delivery tech in polio vaccination campaign

By Nick Paul Taylor

PharmaJet has struck an agreement covering the use of its Tropis needle-free injection system in Nigeria, positioning vaccinators to deploy the technology in a project intended to tackle a poliovirus outbreak.

Viatris prevails in another patent feud over AZ's blockbuster asthma med Symbicort

By Fraiser Kansteiner

Viatris and Kindeva declared victory over a fourth patent on AZ’s drug-device combo Symbicort, which brought home more than $2.7 billion in sales for the British pharma last year.

Satsuma in the red after 2nd phase 3 migraine flop spurs search for strategic alternatives

By Nick Paul Taylor

New device, new trial, same flop. That is the story at Satsuma Pharmaceuticals, which suffered a second stock-crushing phase 3 bellyflop after tweaks to its migraine nasal drug delivery device failed to yield an asset capable of beating placebo.

2022's Fiercest Women in Life Sciences

By Andrea Park

2022 is undoubtedly a fraught time in the history of the women’s movement, but it is also an inspiring one, as people from every corner of the globe come together in support of the idea that women deserve equal rights. That double-edged sentiment echoes throughout this year’s list of the 20 fiercest women in life sciences.
 
Fierce podcasts

Don't miss an episode

'The Top Line': Fierce Biotech's Cell & Gene Therapy Forum

This week on “The Top Line,” we share some highlights from Fierce Biotech's Cell and Gene Therapy Forum in case you missed it.

‘The Top Line’: Philips' plans to cut costs amid ongoing recalls

'Podnosis': Charity care policies, Fierce's Women of Influence

 

Resources

eBook

Using Digital Therapies and Patient Engagement to Improve Clinical Outcomes

See how digital therapeutics (DTx) combined with patient engagement software offer a new opportunity for life science organizations (LSOs) to better serve and support patients. Download the guide from Health Catalyst to learn more.

Sponsored by: Health Catalyst

Whitepaper

THE BIODRUG REVOLUTION

Accelerating bioproduction towards high performance and scale

Sponsored by: Capgemini Americas Inc.

Whitepaper

EHR vs Registry Data for RWE – Heart Failure as a Case Study

Electronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs?

Sponsored by: Veradigm Health

Whitepaper

Commercializing Gene Therapies – Supply Chain Considerations

This paper outlines how gene therapy supply chains are different from traditional biopharma products, as well as the factors that are essential to success.

Sponsored by: Blue Matter

Whitepaper

Navigating the Data Deluge: Turning Data Into Insight Across the Health Care and Life Sciences Industries

Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem.

Sponsored by: NTT DATA

Whitepaper

The Most Suitable Dosage Form Technologies for the Oral Delivery of Lipid-Based Formulations

What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations?

Sponsored by: Catalent

Research

Versatility of Softgel Technology - Encapsulation of a Volatile Compound

Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound.

Sponsored by: Catalent

Whitepaper

Lipid-Based Drug Delivery System to Bring Poorly Soluble Drugs to Market

How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market?

Sponsored by: Catalent

Webinar

The Faster Path From Pre-Filled Syringe to Auto-Injector

Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar.

Sponsored by: Catalent Biologics

Whitepaper

Formulation Strategies When Transitioning From Vial to PFS

Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care.

Sponsored by: Catalent Biologics

Whitepaper

Softgel Formulation Enables Oral Delivery of Testosterone

Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy.

Sponsored by: Catalent

Whitepaper

Strategies for the Optimal Scale-up & Tech Transfer of Oral Small Molecules

Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success.

Sponsored by: Catalent

 

Upcoming Fierce Events

14-16
Nov
European Trial Master File Summit
London, UK
15-16
Nov
Fierce Diversity, Equity & Inclusion Forum
Free Virtual Event
30-1
Nov-Dec
Launch Readiness for Medical Affairs & Communications Teams
Virtual Event
10
Jan
Fierce JPM Week
San Francisco, CA
17-19
Jan
Fierce JPM Week - Virtual Event
Virtual Event

View all events